Evolution of Our Understanding of XIAP Deficiency.

Front Pediatr

Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Published: June 2021

X-linked inhibitor of apoptosis (XIAP) deficiency is a rare inborn error of immunity first described in 2006. XIAP deficiency is characterised by immune dysregulation and a broad spectrum of clinical manifestations, including haemophagocytic lymphohistiocytosis (HLH), inflammatory bowel disease (IBD), hypogammaglobulinemia, susceptibility to infections, splenomegaly, cytopaenias, and other less common autoinflammatory phenomena. Since the first description of the disease, many XIAP deficient patients have been identified and our understanding of the disease has grown. Over 90 disease causing mutations have been described and more inflammatory disease manifestations, such as hepatitis, arthritis, and uveitis, are now well-recognised. Recently, following the introduction of reduced intensity conditioning (RIC), outcomes of allogeneic haematopoietic stem cell transplantation (HSCT), the only curative treatment option for XIAP deficiency, have improved. The pathophysiology of XIAP deficiency is not fully understood, however it is known that XIAP plays a role in both the innate and adaptive immune response and in immune regulation, most notably through modulation of tumour necrosis factor (TNF)-receptor signalling and regulation of NLRP3 inflammasome activity. In this review we will provide an up to date overview of both the clinical aspects and pathophysiology of XIAP deficiency.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247594PMC
http://dx.doi.org/10.3389/fped.2021.660520DOI Listing

Publication Analysis

Top Keywords

xiap deficiency
24
xiap
8
pathophysiology xiap
8
deficiency
6
disease
5
evolution understanding
4
understanding xiap
4
deficiency x-linked
4
x-linked inhibitor
4
inhibitor apoptosis
4

Similar Publications

The Management of Internal Fistulizing Crohn's Disease in a Child: More Than Meets the Eye.

Gastroenterology

October 2024

Paediatric Gastroenterology, Great Ormand Street Hospital, London, United Kingdom; Juliet Keidan Institute of Pediatric Gastroenterology, The Eisenberg R&D Authority, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel. Electronic address:

View Article and Find Full Text PDF

Hemophagocytic Lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS) in children with inflammatory bowel disease (IBD) has been reported only anecdotally. This study aimed at describing the clinical features and outcomes of children diagnosed with both IBD and HLH/MAS. Data on IBD and HLH/MAS characteristics, biochemical, microbiological and genetic assessments, treatments, and outcomes were collected from the Italian Pediatric IBD Registry and presented using descriptive statistics.

View Article and Find Full Text PDF

Human Genetic and Immunological Determinants of SARS-CoV-2 Infection and Multisystem Inflammatory Syndrome in Children.

Clin Exp Immunol

July 2024

Laboratory of Clinical Immunology, Inflammation and Allergies (LICIA), Faculty of Medicine and Pharmacy, Hassan II University, Casablanca 20250, Morocco.

Article Synopsis
  • SARS-CoV-2 causes pneumonia and severe respiratory issues, especially in patients with genetic defects in type I interferon, impacting individuals differently based on age and gender.
  • About 3-5% of critical COVID-19 patients under 60 years have genetic defects in interferon production, while around 15-20% of those over 70 show autoantibodies against type I interferons.
  • This review discusses the links between genetic and immunological factors contributing to severe COVID-19 and pediatric multisystem inflammatory syndrome (MIS-C), emphasizing the need for more research to develop targeted treatments and strategies for future viral infections.
View Article and Find Full Text PDF
Article Synopsis
  • * A 39-year-old man with XIAP deficiency faced severe complications including ARDS from PJP pneumonia and organ failure from a Mycobacterium infection.
  • * The case underscores the difficulties in treating XIAP deficiency and highlights the need for better awareness and research to enhance patient outcomes.
View Article and Find Full Text PDF

Deficiency of X-linked inhibitor of apoptosis protein (XIAP) is a rare genetic condition that can present with recurrent episodes of hemophagocytic lymphohistiocytosis (HLH), though the exact mechanisms leading to this hyperinflammatory disorder are unclear. Understanding its biology is critical to developing targeted therapies for this potentially fatal disease. Here, we report on a novel multiexonic intragenic duplication leading to XIAP deficiency with recurrent HLH that demonstrated complete response to interleukin (IL)-1β blockade.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!